Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 6.1% | 2.6% | 10.9% |
| 2025 |
|---|
| 16.7% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 6.1% | 2.6% | 10.9% |
| 2025 |
|---|
| 16.7% |
Longleaf Partners Global Fund delivered solid 2025 performance with 16.72% returns, beating their inflation plus 10% hurdle despite trailing indices due to underweight Financials and cash holdings. The fund completed a strategic merger with their International Fund, demonstrating confidence in the Global strategy. Portfolio positioning reflects late-cycle caution with 45% in defensive sectors and cash, significantly higher than previous market peaks in 2007 and 2021. Key contributors included Canal+ benefiting from favorable UEFA rights renewal, Glanbia's operational improvements and share buybacks, and Millicom's strong FCF inflection before exit. Notable detractors were life sciences companies Bio-Rad and Avantor facing industry headwinds, and Exor despite value-creating capital allocation moves. Management emphasizes their portfolio's reduced leverage compared to prior cycles, with bond spreads half the levels of 2007 and 2021. The fund maintains conviction in owning quality companies with strong management partners positioned to outperform when market speculation inevitably disappoints, supported by their disciplined three rules framework implemented in 2022.
Southeastern maintains a concentrated portfolio of undervalued, high-quality companies with strong free cash flow generation and excellent management teams, positioned defensively for late-cycle market conditions while capitalizing on the firm's 50-year value investing expertise.
The fund expects continued focus on quality over quantity in communications, with more Research Perspectives notes and P/V Podcasts planned. Management believes there will be virtue in all markets from owning real companies on offense when excessive speculation is widespread, with understandable, durable, FCF generating assets run by great partners positioned to win when the tide goes out.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 14 2026 | 2025 Q4 | ANGI, AVTR, BIO, CNH, CNX, DHER.DE, EXOR.MI, F, FI, GLAN.L, GRUMA.MX, IAC, JFC.PS, KHC, MAT, MGM, PHG, REGN, STLA, TIGO, UNH | Buybacks, FCF, global, Holdings, Media, Quality, value |
CAN LN GLB LN TIGO IAC KHC MGM ANGI BIO AVTR |
The fund maintains a concentrated portfolio of undervalued stocks trading at low P/V ratios in the low-60s%. Management emphasizes finding defensive growers like consumer staples… |
| Oct 15 2025 | 2025 Q3 | 4613 JP, ACI, CAN LN, CNX, EXO NA, GLB LN, IAC, MAT, PCH, PHG, PVH, RYN | Compounding, free cash flow, Global Equities, Quality, Value Investing |
4613 JP PVH |
Longleafs Global Fund emphasizes owning real-asset and cash-flow-generating businesses while avoiding speculative overvaluation driven by AI exuberance. Management sees opportunity in undervalued holdings such as… |
| Jul 22 2025 | 2025 Q2 | CAN LN, FDX, GLB ID, KHC, LG FP, REGN | diversification, fundamentals, global value, Margin Of Safety, valuation | CAN LN | The letter focuses on global value opportunities created by uneven earnings expectations and investor behavior. Management highlights a portfolio trading at a deep discount to… |
| Apr 12 2025 | 2025 Q1 | ACI, BOL, CNX, FDX, GMKKY, IAC, TIGO | - | - | - |
| Jan 16 2025 | 2024 Q4 | CNX, ERF FP, FIS, IAC, K, MGM, PRX NA, TIGO, VIV FP, WBD | - | - | - |
| Oct 16 2024 | 2024 Q3 | CNX, DHER GR, ERF FP, FDX, K, MGM, PROSY | - | - | - |
| Jul 23 2024 | 2024 Q2 | BIO, DELHY, ERF FP, FDX, PROSY, TIGO | - | - | - |
| May 7 2024 | 2024 Q1 | CNX, FDX, FIS, WBD | - | - | - |
| Jan 17 2024 | 2023 Q4 | EXO NA, FDX, FFX GR, GE, LUMEN SS, LYV, PVH, TIGO, WBD | - | - | - |
| Dec 10 2023 | 2023 Q3 | CNX, DHE GR, GE, IAC, MAT, WBD | - | - | - |
| Jul 19 2023 | 2023 Q2 | GOOG, IAC, LYV, TIGO, WBD | - | - | - |
| Apr 20 2023 | 2023 Q1 | DIS, FDX, GE, LUMEN, MGM, TIGO | - | - | - |
| Sep 2 2023 | 2022 Q4 | AMG, CNX, GE, IAC, LUMN, TIGO, WBD | - | - | - |
| Sep 11 2022 | 2022 Q3 | CYTH SW, FDX, IAC | - | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
BuybacksShare repurchases in 2024 and 2025 hit consecutive records as companies raced to meet Tokyo Stock Exchange capital efficiency mandates. Buybacks were a primary driver of the market's 20% climb in the first half of FY2025. |
Share Repurchases Capital Efficiency TSE Mandates Shareholder Returns Records |
MediaWarner Bros Discovery was the top contributor as multiple parties submitted acquisition offers, with Netflix acquiring the Streaming and Studios business while Global Networks spins to shareholders. Paramount Skydance made a $30 per share offer for the entire company, creating a bidding war that unlocked shareholder value. |
Streaming M&A Content Entertainment Bidding | |
ValueManager emphasizes investing in controlled companies trading at significant discounts to NAV, with European holding companies showing discounts of 30-68%. The strategy focuses on securities mispricing where real value exists, contrasting with overvalued technology stocks. |
Discounts NAV Mispricing Undervalued Controlled | |
| 2025 Q3 |
QualityThe portfolio has shifted toward higher quality businesses with better profitability, lower leverage, and less volatile earnings. Quality stocks underperformed significantly in 2025, creating attractive entry points for value investors. The manager maintains price discipline while seeking quality companies trading at discounts to intrinsic value. |
Quality Profitability Leverage Earnings |
ValueThe manager continues to find attractive value opportunities despite expensive markets, purchasing undervalued companies like Centene, GlaxoSmithKline, Carrefour and PayPal trading at low multiples with strong fundamentals. |
Undervalued Low Multiples Contrarian Opportunistic | |
| 2025 Q2 |
ValueThe manager continues to find attractive value opportunities despite expensive markets, purchasing undervalued companies like Centene, GlaxoSmithKline, Carrefour and PayPal trading at low multiples with strong fundamentals. |
Undervalued Low Multiples Contrarian Opportunistic |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 15, 2025 | Fund Letters | Ross Glotzbach | 4613 JP | Kansai Paint Co., Ltd. | Materials | Specialty Chemicals (Paints & Coatings) | Bull | NYSE | buybacks, Coatings, dividends, Europe, India, Margins, Optimization | Login |
| Oct 15, 2025 | Fund Letters | Ross Glotzbach | PVH | PVH Corp. | Consumer Discretionary | Apparel, Accessories & Luxury Goods | Bull | NYSE | Apparel, brands, buybacks, DTC, Eps, Margins, valuation | Login |
| Jul 22, 2025 | Fund Letters | Ross Glotzbach | CAN LN | Canal+ SA | Communication Services | Broadcasting | Bull | London Stock Exchange | Africa, Pay-TV, spin-off, Super-Aggregator, synergies, undervalued | Login |
| Jan 14, 2026 | Fund Letters | Ross Glotzbach | CAN LN | Canal+ S.A. | Communication Services | Broadcasting | Bull | New York Stock Exchange | Africa, broadcasting, Freecashflow, Sportsrights, Subscriptions | Login |
| Jan 14, 2026 | Fund Letters | Ross Glotzbach | GLB LN | Glanbia plc | Consumer Staples | Packaged Foods | Bull | New York Stock Exchange | buybacks, Capitalallocation, Margins, Nutrition, Simplification | Login |
| Jan 14, 2026 | Fund Letters | Ross Glotzbach | TIGO | Millicom International Cellular S.A. | Communication Services | Wireless Telecommunication Services | Bull | NASDAQ | buybacks, deleveraging, dividends, Freecashflow, Telecom | Login |
| Jan 14, 2026 | Fund Letters | Ross Glotzbach | IAC | IAC Inc. | Communication Services | Interactive Media & Services | Bull | NASDAQ | buybacks, Holdingcompany, spinoff, valuation | Login |
| Jan 14, 2026 | Fund Letters | Ross Glotzbach | KHC | The Kraft Heinz Company | Consumer Staples | Packaged Foods | Bull | NASDAQ | management, Packagedfoods, Split, valuation | Login |
| Jan 14, 2026 | Fund Letters | Ross Glotzbach | MGM | MGM Resorts International | Consumer Discretionary | Casinos & Gaming | Bull | New York Stock Exchange | Assetrecycling, buybacks, cashflow, Gaming, Vegas | Login |
| Jan 14, 2026 | Fund Letters | Ross Glotzbach | ANGI | Angi Inc. | Communication Services | Interactive Media & Services | Bull | NASDAQ | marketplace, turnaround, valuation | Login |
| Jan 14, 2026 | Fund Letters | Ross Glotzbach | BIO | Bio-Rad Laboratories, Inc. | Health Care | Life Sciences Tools & Services | Bull | New York Stock Exchange | buybacks, Freecashflow, lifesciences, research | Login |
| Jan 14, 2026 | Fund Letters | Ross Glotzbach | AVTR | Avantor, Inc. | Health Care | Life Sciences Tools & Services | Bear | New York Stock Exchange | Execution, guidance, lifesciences, turnaround | Login |
| TICKER | COMMENTARY |
|---|---|
| ANGI | One specific simplification move IAC made this year was the spinoff of Angi, the home services marketplace. We purchased more Angi shares post-spin at a depressed price and then sold our position as evidence of their multi-year turnaround heading down the right path caused the stock to reach our appraisal. |
| AVTR | We added a partial position of Avantor to the portfolio in the second half of the year after (and then while) the company had some self-inflicted ups and downs. It is probable that the worst is in the past for Avantor after a leadership change and guidance reset, but we felt it best to exit and book a loss before year end. |
| BIO | Healthcare has been out of favor in recent years, weighed down by post-Covid headwinds, but we find the highly regulated sector to be structurally attractive given growing demand and significant barriers to entry. With a market cap around $6.5 billion, Bio-Rad Laboratories is smaller than our typical investment, but the company dominates the niches it serves within the areas of life-science research and diagnostics. Vertical integration historically has resulted in strong recurring revenue for the company, and its diversified customer base has further supported stability. Notably, Bio-Rad maintains a one-third stake in German biopharma company Sartorius that has grown significantly since its purchase and provides Bio-Rad with an economic exposure beyond its core businesses. |
| CNH | CNH Industrial hurt us due to cyclical headwinds but we believe will likely recover in due course. |
| CNX | CNX Resources Corporation was our top contributor for the quarter. Natural gas prices rose into the end of the quarter. The gain was largely weather-driven and with $5/mcf levels viewed as unsustainable in our long-term projections—CNX benefited in the short-term from a favorable near-term pricing backdrop. At the same time, the company continued to execute consistently, delivering on production targets, generating strong free cash flow, and returning capital through a disciplined and accretive share repurchase program, which together supported multiple expansion. |
| EXOR.MI | European holding company Exor had a disappointing stock market performance in the quarter and year, with the share price correcting in 2025. This is despite a series of capital allocation and portfolio moves that fundamentally enhanced intrinsic value per share and continue to give us confidence in the leadership of CEO John Elkann. Exor executed a partial sale of Ferrari early in the year at all-time highs, roughly 40% above year end levels, and redeployed the proceeds into Exor's own shares at a sizable holding company discount, via an efficient one-time Dutch auction. Alongside that move, Exor increased its stake in Philips at good prices to roughly a 19% stake from 15% earlier in the year and supported the complex sale of CNH's spinoff Iveco Group's two separate businesses. Yet the market's cooling toward Ferrari and a weak stock market year for both Stellantis and CNH (despite value per share at both not moving much) have weighed on Exor's quoted price. |
| F | For insight into the real economy operating beneath this AI and data center boom, we must look elsewhere within the S&P 500, including bellwethers like Ford |
| FI | Notable detractors from performance came from Fiserv (-43bps absolute and -39bps relative) |
| GLAN.L | Irish nutrition, ingredients and dairy company Glanbia contributed for the year. After a tough start in 2025, momentum in its core Performance Nutrition business improved from low single-digit growth rates. Management also delivered tangible progress on portfolio rationalization and capital allocation. The company added to its ongoing buyback program by opportunistically repurchasing an additional approximately 3% of its own shares at a discount in connection with Tirlán's October 2025 placement, helping reduce the long-standing overhang from its largest shareholder (today an 18% holder, down from 24% earlier this year and higher levels before). At the same time, Glanbia's management team advanced its simplification agenda by executing on the announced sale of margin-dilutive SlimFast and Body&Fit assets, sharpening focus on the higher-quality Performance Nutrition branded franchises. |
| IAC | Digital holding company IAC has signaled its plans to dispose of all assets besides People Inc. and an approximate 25% stake in MGM. Chairman Barry Diller is focused on closing the valuation disconnect as no value has been ascribed by the markets to IAC's assets beyond MGM for too long. Share repurchase and increasing the stake in MGM are the main capital allocation options, and the company is already acting on both. |
| JFC.PS | During the quarter, we continued building our position in Philippine franchise giant Jollibee. The organisation pivoted away from empire-building and re-focused on what they do best: selling chicken. They're aggressively expanding the core Jollibee brand into the United States, where early signs are promising |
| KHC | Global food and beverage producer Kraft was a detractor for 2025. The market is overly focused on the lack of near term growth in North America and not focusing enough on the value-creating potential of the company's upcoming split into two businesses: the higher-growth Global Taste Elevation Co. which contains the Heinz brand and should garner a teens EBITDA multiple, and the stable remaining company comprised largely of North American grocery products. |
| MAT | Children's toy, media, and consumer products creator Mattel was a contributor for the quarter and the year. The company is in its strongest position in over 10 years, and there are multiple ways to win. Over 80% of Mattel's value comes from growing power brands like Hot Wheels, Barbie, and UNO. Mattel has a strong balance sheet which allowed material stock repurchases of $600 million in 2025, and we believe additional share repurchase will come at these discounted prices in 2026. |
| MGM | Casino operator MGM Resorts had a relatively weaker 2025 in Las Vegas due to difficult comparisons after multiple years of strength. A significant turnaround at BetMGM plus strong performances at non-Las Vegas regional properties and Macau helped steady the consolidated business throughout the year. Management has corrected some pricing mistakes while making moves to narrow their focus. |
| PHG | Philips, the Dutch healthcare company, represents part of the Agnelli family's diversification away from the auto industry. |
| REGN | Performance was driven by strength in large-cap longs, specifically Regeneron |
| STLA | Stellantis is one of three separately listed businesses that account for around half of Exor's net asset value. |
| TIGO | Latin American telecommunications operator Millicom was a contributor for the year. The company extended its strong 2024 performance through 2025, with the share price tracking operational delivery and the visible inflection in equity FCF we flagged in prior letters. This was driven by a focused new management team and an aligned majority shareholder partner in Iliad Group (Atlas). The business exceeded its already twice-raised 2024 FCF guidance and guided to material further growth in 2025, while reaching its 2.5x leverage target and increasing dividends and buybacks. The discount to our appraisal narrowed with this positive performance and solid Colombian M&A news. What was an attractive outlier at a double-digit dividend yield earlier in the year has now aligned with peers at mid-single-digit levels. With the value gap largely closed and limited upside remaining on a risk-adjusted basis, portfolio discipline dictated our exit in the third quarter. |
| UNH | United Healthcare had its own challenges, with surprise losses, a complicated political situation, and leadership changes. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||